Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Series C Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Total
Beginning balance, shares at Mar. 31, 2019 2 1,316,335        
Beginning balance, value at Mar. 31, 2019 $ 2 $ 184,074 $ (169,238) $ (4,349) $ 10,489
Cumulative adjustment resulting from adoption of ASU   (59) (59)
Stock based compensation related to issuance of common stock restricted stock grants, shares   835        
Stock based compensation related to issuance of common stock restricted stock grants, value   20 20
Stock-based compensation expense, net of forfeitures   272   272
Foreign currency translation adjustment   67 67
Net income   715 715
Ending balance, shares at Jun. 30, 2019 2 1,317,170        
Ending balance, value at Jun. 30, 2019 $ 2 184,366 (168,582) (4,282) 11,504
Beginning balance, shares at Mar. 31, 2020 2 1,777,483        
Beginning balance, value at Mar. 31, 2020 $ 2 186,559 (172,246) (5,610) 8,705
Stock based compensation related to issuance of common stock restricted stock grants, shares 3,086        
Stock based compensation related to issuance of common stock restricted stock grants, value 18 18
Stock-based compensation expense, net of forfeitures 45 45
Issuance of common stock due to warrant exercises, shares 169,167        
Issuance of common stock due to warrant exercises, value 1,490 1,490
Conversion of Series C convertible preferred stock into common stock, shares (2) 17,222        
Conversion of Series C convertible preferred stock into common stock, value
Foreign currency translation adjustment 167 167
Net income 240 240
Ending balance, shares at Jun. 30, 2020 0 1,966,958        
Ending balance, value at Jun. 30, 2020 $ 2 $ 188,112 $ (172,006) $ (5,443) $ 10,665